Close Menu
Home › Biocartis, Covance Sign Commercialization Agreement for Idylla

Biocartis, Covance Sign Commercialization Agreement for Idylla

Apr 23, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis has announced that it has signed a commercialization agreement with Covance, the clinical research organization owned by Laboratory Corporation of America, to offer its Idylla platform and oncology assay menu to Covance's global customer base.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
16
Featured Webinar

Using Next-Generation Sequencing to Detect Genomic Mutations in Hematologic Malignancies

Sponsored by
ArcherDX

This webinar will discuss a next-generation sequencing approach for detecting genomic mutations in hematologic maglignancies.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Molecular Diagnostics

  1. FDA Stepping Up Actions Against PGx Testing, Forcing Some Labs to Stop Reporting Drug Information

  2. Complex Genetic Testing Errors Emerge Amid Increasing Panel Use, Consumer Access, Case Series Finds

    Premium

  3. Inflammatix Preps Immune-Response Sepsis Dx for FDA Clinical Trial, Lays Out Future Test Plans

    Premium

  4. Myriad Genetics Stock Plummets on Lower-Than-Expected Q4 Revenues, FDA Interactions on GeneSight

  5. Adaptive Biotechnologies Plans New Product Launches, Expanded FDA Label for ClonoSeq

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.